Abstract
Bone metastases are one of the most common events in patients with prostate carcinoma. PTH-rP, a protein produced by prostate carcinoma and other epithelial cancers, is a key agent for the development of bone metastases. A PTH-rP-derived peptide, designated PTR-4 was identified, which is capable to bind HLA-A2.1 molecules and to generate PTH-rP-specific cytotoxic T cell (CTL) lines from healthy HLA-A2.1+ individual peripheral-blood-mononuclear-cells (PBMC). In this model, we investigated the in vitro possibility of generating an efficient PTH-rP specific CTL response by cyclical stimulations with IL-2 and PTR-4 peptide-pulsed autologous dendritic cells (DC), of HLA-A2.1+ tumour infiltrating lymphocytes (TIL) derived from a patient with metastatic prostate carcinoma. A T cell line generated in this way (called TM-PTR-4) had a CD3+, CD5+, CD4–, CD8+, CD45Ro+, CD56– immunophenotype and a HLA-A2.1 restricted cytotoxic activity to PTR-4-peptide pulsed CIR-A2 (HLA-A2.1+) target cells, PTH-rP+/HLA-A2.1+ CIR-A2 transfected with PTH-rP gene, prostate carcinoma LNCaP cells, and autologous metastatic prostate cancer cells (M-CaP). These lymphocytes were not cytotoxic to HLA-A2.1+ targets not producing PTH-rP, such as peptide-unpulsed CIR-A2 and colon carcinoma SW-1463, cell lines. Our results provide evidence that PTR-4 peptide-pulsed autologous DC may break the tolerance of human TIL against the autologous tumour by inducing a PTH-rP-specific CTL immune reaction. In conclusion PTR-4 peptide-pulsed autologous DC may be a promising approach for vaccine-therapy and antigen-specific CTL adoptive immunotherapy of hormone-resistant prostrate cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abrams SI, Dobrzanski MJ, Wells DT, Stanziale SF, Zaremba S, Masuelli L, Kantor JA and Sclom J (1995) Peptide-specific activation of cytotoxic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur J Immunol 25: 2588–2597
Arienti F, Belli F, Rivoltini L, Gambacorti-Passerini C, Furlan L, Mascheroni L, Prada A, Rizzi M, Marchesi E, Vaglini M, Parmiani G and Cascinelli N (1993) Adoptive Immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor infiltrating lymphocytes selected in vitro with low doses of IL- 2. Cancer Immunol Immunother 36: 315–322
Bell D, Young JW and Banchereau J (1999) Dendritic cells. Adv Immunol 72: 255–324
Boyum A (1968) A one stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field. Scand J Clin Lab Invest 97, ( Suppl): 51–76
Cerundolo V, Alexander J, Anderson K, Lamb C, Cresswell P, McMichael A, Gotch F and Townsend A (1990) Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 345: 449–452
Coffey DS (1993) Prostate Cancer. An overview of an increasing dilemma. Cancer 71: 880–886
Correale P, Tagliaferri P, Celio L, Genua G, Montagnani S and Bianco AR (1991) Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. Eur J Cancer 27: 1393–1395
Correale P, Procopio A, Celio L, Caraglia M, Genua G, Coppola V, Pepe S, Normanno N, Vecchio I, Palmieri G, Montagnani S, Tagliaferri P and Bianco AR (1992) Phorbol Myristate Acetate induces resistance of human melanoma cells to natural killer- and lymphokine activated killer (LAK) -mediated cytotoxicity. Cancer Immunol Immunother 34: 272–278
Correale P, Caraglia M, Fabrocini A, Guarrasi R, Pepe S, Patella V, Marone G, Pinto A, Bianco AR and Tagliaferri P (1995) Bryostatin 1 enhances lymphokine activated killer (LAK) sensitivity and modulates very late activation antigen (VLA) profile of cultured human tumor cells. Anticancer Drugs 6: 285–290
Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J and Tsang KY (1997) In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 89: 293–300
Correale P, Campoccia G, Tsang KY, Micheli L, Cusi MG, Sabatino M, Bruni G, Sestini S, Petrioli R, Pozzessere D, Marsili S, Fanetti G, Giorgi G and Francini G (2001a) Recruitment of dendritic cells and enhanced antigen specific immune-reactivity in cancer patients treated with hrGM-CSF (molgramostim) and hr IL-2: results from a Phase Ib Clinical Trial. Eur J Cancer 37, (7):892–902
Correale P, Cusi MG, Sabatino M, Micheli L, Pozzessere D, Nencini C, Valensin PE, Giorgi G, Zurbriggen R, Gluck R and Francini G (2001b) Tumour associated antigen (TAA) specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes. Eur J Cancer, (in press)
Fenton RG, Taub DD, Kwak LW, Smith MR and Longo DL (1993) Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst 85: 1294–1302
Francini G, Petrioli R, Manganelli A, Cintorino M, Marsili S, Aquino A and Mondillo S (1993) Weekly chemotherapy in advanced prostatic cancer. (6):Br J Cancer 67: 1430–1436
Francini G, Pozzessere D, Campoccia G, Sabatino M, Petrioli R, Fanetti G, Lozzi L, Neri P and Correale P (2001) Generation and characterization of Human Cytotoxic T Lymphocytes Specific For HLA-A2-1 Binding Peptides Derived From Parathyroid-related Protein. Submitted for publication.
Frost P, Ng CP, Belldegrun A and Bonavida B (1997) Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK) mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. (1):Cell Immunol 180: 70–83
Grabbe S, Beissert S, Schwarz T and Granstein RD (1995) Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?. Immunol Today 16: 117–121
Guadagni F, Witt PL, Robbins PF, Schlom J and Greiner WJ (1990) Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-α. Cancer Res 50: 6248–6255
Guise TA (1997) Parathyroid hormone–related protein and bone metastases. Cancer 80: 1572–1580
Hortobagyi G (1991) Bone metastases in breast cancer patients. (5):Semin Oncol 18: 11–15
Houbiers JG, Nijman HW, van der Burg SH, Drijfhout JW, Kenemens P, van de Velde CJ, Brand M, Momberg F, Kast WM and Melief CJM (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 23: 2072–2077
Jung S and Schluesener HJ (1991) Human T lymphocytes recognize a peptide of single point-mutated oncogene ras proteins. J Exp Med 173: 273–276
Liuykx-de Bakker SA, Gruijl TD, Scheper RJ, Wagstaff J and Pinedo HM (1999) Dendritic cells: a novel therapeutic modality. Ann Oncol 10: 21–27
Marincola FM (1994) Interleukin 2. Biol Ther Cancer Updates 4: 1–16
Markowicz S and Engleman EG (1990) Granulocyte-macrophage colony stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 85: 955–961
Melero I, Bach N and Chen L (1997) Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Life Sciences 60: 2035–2041
Panelli MC and Marincola F (1998) Immunotherapy update: from interleukin-2 to antigen specifictherapy. Educational Book from the 34th Annual Meeting of the American Society of Clinical Oncology, 467–469
Pierce WC, Belldegrun A and Figlin RA (1995) Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. (1):Semin Oncol 22: 74–80
Restifo NP and Sznol M (1997) Cancer Principles and Practice of Oncology. Lippincott: Philadelphia
Romani N, Reider D, Heuer M, Ebner S, Kämpgen E, Eibl B, Niederwieser D and Schuker G (1996) Generation of mature dentritic cells from human blood. An improvement method with special reagent to clinical applicability. J Immunol Methods 196: 137–151
Rosenberg SA, Yang J, Schwartzentruber DJ, Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Sznol M, Schwarz SL, Spiess PJ, Wunderlich JR, Seipp CA, Einhorn JH, Rogers Freezer L and White DE (1998) Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163: 1690–1695
Rosenberg SA, Yannelli JR, Yang JC, Topalian L, Schwartzentruber J, Weber S, Parkinson R, Seipp A, Einhorn HD and White E (1994) Treatment of patients with metastatic tumor infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86: 1159–1166
Rubens RD (1998) Bone metastases – the clinical problem. Eur J Cancer 34: 210–213
Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL and Murphy GP (1998) Evaluation of Phase I/II clinical trial in prostate cancer with dendritic cells and PSMA peptides. Prostate 36: 39–44
Tagliaferri P, Guarrasi R, Caraglia M, Morelli D, Fabbrocini A, Correale P and Bianco AR (1998) Tumour cell resistance to non MHC-restricted lymphocytes: molecular mechanisms and clinical implications. Cancer Immunol Immunother 46: 121–127
Topalian SL and Rosenberg SA (1989) Tumour specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142: 3714–3725
Topalian SL, Muul LM, Solomon D and Rosenberg SA (1987) Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102: 127–131
Tsang KY, Nieroda CA, De Filippi R, Chung YK, Yamaue H, Greiner JW and Schlom J (1994) Induction of human cytotoxic T- cell lines directed against point-mutated p21 ras-derived synthetic peptides. Vaccine Res 3: 183–193
Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM and Schlom J (1995) Generation of human cytotoxic T cells specific for human carcinoembrionic antigen epitopes from patients immunized with recombinant vaccinia CEA vaccine. J Natl Cancer Inst 87: 982–990
Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T (1991) A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 254: 1643–1647
Vinholes J, Coleman R and Eastell R (1996) Effects of bone metastases on bone metabolism: Implications diagnosis, imaging and assessment of response to cancer treatment. Cancer Treatment Reviews 22: 289–331
Vose BM and Moore M (1985) Human tumor infiltrating lymphocytes: a marker of host response. Semin Hematol 22: 27–29
Whiteside TL (1991) Tumour-infiltrating lymphocytes as antitumor effector cell. Biotherapy 5: 47–61
Whiteside TL and Parmiani G (1994) Tumour infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother 39: 15–21
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Correale, P., Micheli, L., Vecchio, M. et al. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Br J Cancer 85, 1722–1730 (2001). https://doi.org/10.1054/bjoc.2001.2136
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.2136
Keywords
This article is cited by
-
In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse
British Journal of Cancer (2003)
